[go: up one dir, main page]

WO2004073619A3 - Ccr8 antagonists - Google Patents

Ccr8 antagonists Download PDF

Info

Publication number
WO2004073619A3
WO2004073619A3 PCT/US2004/004256 US2004004256W WO2004073619A3 WO 2004073619 A3 WO2004073619 A3 WO 2004073619A3 US 2004004256 W US2004004256 W US 2004004256W WO 2004073619 A3 WO2004073619 A3 WO 2004073619A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr8
ccr8 antagonists
benzenesulfonamide
antagonists
nominated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/004256
Other languages
French (fr)
Other versions
WO2004073619A2 (en
Inventor
Jian Jin
Jeffrey K Kerns
Feng Wang
Yonghui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of WO2004073619A2 publication Critical patent/WO2004073619A2/en
Publication of WO2004073619A3 publication Critical patent/WO2004073619A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to certain substituted benzenesulfonamide and their use for inhibiting the chemokine receptor nominated CCR8. The generic structure for these compounds, as defined herein is that of a benzenesulfonamide of formula (I).
PCT/US2004/004256 2003-02-14 2004-02-13 Ccr8 antagonists Ceased WO2004073619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44756003P 2003-02-14 2003-02-14
US60/447,560 2003-02-14

Publications (2)

Publication Number Publication Date
WO2004073619A2 WO2004073619A2 (en) 2004-09-02
WO2004073619A3 true WO2004073619A3 (en) 2005-03-24

Family

ID=32908458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004256 Ceased WO2004073619A2 (en) 2003-02-14 2004-02-13 Ccr8 antagonists

Country Status (1)

Country Link
WO (1) WO2004073619A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20055498A0 (en) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamides
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2010118063A2 (en) 2009-04-06 2010-10-14 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
KR101712035B1 (en) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. Therapeutic compounds and compositions
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JP5967827B2 (en) * 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Therapeutically active compounds for the treatment of cancer characterized by having an IDH variant
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
CA2822432C (en) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
CN108451955B (en) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 Pyruvate kinase activators for therapy
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
JP6529492B2 (en) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutant Inhibitors for the Treatment of Cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
ES2899852T3 (en) 2014-12-17 2022-03-15 Pimco 2664 Ltd N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(-4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
EP4344703A1 (en) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
MX390531B (en) 2015-10-15 2025-03-20 Servier Lab COMBINATION THERAPY TO TREAT MALIGNANT TUMORS.
MA43000B1 (en) 2015-10-15 2021-11-30 Celgene Corp Combination therapy for the treatment of malignant tumors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN115989223B (en) * 2020-07-03 2024-09-20 南京艾美斐生物医药科技有限公司 Methods and compositions for targeting Tregs using CCR8 inhibitors
AR131211A1 (en) 2022-11-30 2025-02-26 Idorsia Pharmaceuticals Ltd ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133442A (en) * 1994-12-20 2000-10-17 Hoffmann-La Roche Inc. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133442A (en) * 1994-12-20 2000-10-17 Hoffmann-La Roche Inc. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists

Also Published As

Publication number Publication date
WO2004073619A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2004074438A3 (en) Ccr8 antagonists
WO2004073619A3 (en) Ccr8 antagonists
WO2002078693A3 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
WO2003028641A3 (en) Mch receptor antagonists
WO2006044504A8 (en) Cgrp receptor antagonists
HK1054333A1 (en) Heteroaryl urea neuropeptide y y5 receptor antagonists
WO2002081430A3 (en) Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
WO2002060900A3 (en) Antagonists of mcp-1 function and methods of use thereof
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2006020959A3 (en) Substituted benzofused heterocycles
WO2004035569A3 (en) Novel compounds with antibacterial activity
BRPI0518581A2 (en) chromanylurea compounds that inhibit the vanilloid receptor subtype 1 receptor (vr1) and their uses
WO2005000820A3 (en) 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists
WO2004074244A3 (en) Pyrimidine compounds
BR0206595A (en) Compound, pharmaceutical composition, and use of a compound
WO2005113534A3 (en) Cxcr1 and cxcr2 chemokine antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
WO2005049616A8 (en) 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006099268A3 (en) Cgrp receptor antagonists
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
CA2549479A1 (en) Substituted arylpyrazoles as parasiticidal agents
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2006047196A3 (en) Cgrp receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase